Bénédicte Stengel

Bénédicte Stengel

Auto-generated profile, based on publicly available information

Bénédicte Stengel

FCRIN INI-CRCT, Nancy, France

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2014 in JAMA
Verified
Journal Article
Open access
PDF file
JCJosef Coresh
Josef Coresh
Tanvir C TurinTanvir C Turin
Tanvir C Turin
KMKunihiro Matsushita
Kunihiro Matsushita
YSYingying Sang
Yingying Sang
SBShoshana H. Ballew
Shoshana H. Ballew
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
Chronic kidney disease (CKD) is a worldwide public health problem, with increasing prevalence, poor outcomes, and high treatment costs.1 Yet despite the availability of simple laboratory tests to identify people with earlier stages of CKD, there are fewer clinical trials for kidney disease than for other common diseases.2 One contributing reason may be that the established end point (ie, a doubling of serum creatinine concentration from baseline, corresponding to a 57% reduction in estimated glomerular filtration rate [GFR]) used to document CKD progression is a late event, requiring long follow-up periods and large sample sizes.2-4 Improved methods for GFR estimation may allow for use of smaller reductions in estimated GFR (vs a doubling of serum creatinine concentration) as alternative end points to assess CKD progression.4,5 Evaluation of such alternative end points should include their enumeration and quantification of their relationship with future progression to end-stage renal disease (ESRD) across a wide range of settings. Standardized definitions of CKD progression outcomes would also benefit observational studies and clinical practice.

1 October 2017 in The Lancet
Verified
Journal Article
Closed access
ALAdeera Levin
Adeera Levin
MTMarcello Tonelli
Marcello Tonelli
JBJoseph Bonventre
Joseph Bonventre
JCJosef Coresh
Josef Coresh
JDJo-Ann Donner
Jo-Ann Donner
CYChih-Wei Yang
Chih-Wei Yang

12 January 2016 in JAMA
Verified
Journal Article
Open access
PDF file
NTNavdeep Tangri
Navdeep Tangri
MGMorgan E. Grams
Morgan E. Grams
ALAndrew S. Levey
Andrew S. Levey
JCJosef Coresh
Josef Coresh
LALawrence Appel
Lawrence Appel
KIKunitoshi Iseki
Kunitoshi Iseki
Chronic kidney disease (CKD) is increasing in incidence and prevalence worldwide.1 Rates of progression to kidney failure vary among individuals with CKD and depend on the severity of kidney disease, comorbid conditions, and risk of dying before kidney failure onset.2,3 Interventions to slow CKD progression, planning for initiation of dialysis and transplant, and early creation of arteriovenous fistula have been advocated, but these strategies may be expensive and are associated with risks. Treatment would ideally be recommended only for patients at high risk of progression and for whom the benefit exceeds the harm.4,5

12 October 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
YIFU LIYIFU LI
YIFU LI
FSFrancesco Scolari
Francesco Scolari
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
MCMurim Choi
Murim Choi
AGAli G Gharavi
Ali G Gharavi
Ali Gharavi and colleagues report a genome-wide association analysis of IgA nephropathy in over 20,000 individuals of European and East Asian ancestry. They identify genome-wide significant signals at three new loci near VAV3, CARD9 and ITGAM-ITGAX and correlations between genetic risk and pathogen diversity. We performed a genome-wide association study (GWAS) of IgA nephropathy (IgAN), the most common form of glomerulonephritis, with discovery and follow-up in 20,612 individuals of European and East Asian ancestry. We identified six new genome-wide significant associations, four in ITGAM-ITGAX, VAV3 and CARD9 and two new independent signals at HLA-DQB1 and DEFA. We replicated the nine previously reported signals, including known SNPs in the HLA-DQB1 and DEFA loci. The cumulative burden of risk alleles is strongly associated with age at disease onset. Most loci are either directly associated with risk of inflammatory bowel disease (IBD) or maintenance of the intestinal epithelial barrier and response to mucosal pathogens. The geospatial distribution of risk alleles is highly suggestive of multi-locus adaptation, and genetic risk correlates strongly with variation in local pathogens, particularly helminth diversity, suggesting a possible role for host–intestinal pathogen interactions in shaping the genetic landscape of IgAN.

21 January 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPCristian Pattaro
Cristian Pattaro
ATAlexander Teumer
Alexander Teumer
MGMathias Gorski
Mathias Gorski
ACAudrey Y Chu
Audrey Y Chu
MLMan Li
Man Li
CFCaroline S Fox
Caroline S Fox
Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways.

23 December 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
KBKatharina Brück
Katharina Brück
VSVianda S. Stel
Vianda S. Stel
GGGiovanni Gambaro
Giovanni Gambaro
SHStein Hallan
Stein Hallan
HVHenry Völzke
Henry Völzke
OCon behalf of the European CKD Burden Consortium
on behalf of the European CKD Burden Consortium
CKD prevalence estimation is central to CKD management and prevention planning at the population level. This study estimated CKD prevalence in the European adult general population and investigated international variation in CKD prevalence by age, sex, and presence of diabetes, hypertension, and obesity. We collected data from 19 general-population studies from 13 European countries. CKD stages 1–5 was defined as eGFR30 mg/g, and CKD stages 3–5 was defined as eGFR<60 ml/min per 1.73 m2. CKD prevalence was age- and sex-standardized to the population of the 27 Member States of the European Union (EU27). We found considerable differences in both CKD stages 1–5 and CKD stages 3–5 prevalence across European study populations. The adjusted CKD stages 1–5 prevalence varied between 3.31% (95% confidence interval [95% CI], 3.30% to 3.33%) in Norway and 17.3% (95% CI, 16.5% to 18.1%) in northeast Germany. The adjusted CKD stages 3–5 prevalence varied between 1.0% (95% CI, 0.7% to 1.3%) in central Italy and 5.9% (95% CI, 5.2% to 6.6%) in northeast Germany. The variation in CKD prevalence stratified by diabetes, hypertension, and obesity status followed the same pattern as the overall prevalence. In conclusion, this large-scale attempt to carefully characterize CKD prevalence in Europe identified substantial variation in CKD prevalence that appears to be due to factors other than the prevalence of diabetes, hypertension, and obesity.